[Haibu Pharmaceutical] Pregabalin oral solution has successfully been selected in the tenth batch of national centralized procurement!
Classification:
Company News
Recent Events
Release time:
2024-12-16
On December 13, 2024, at the recently concluded opening meeting of the tenth batch of national drug centralized procurement, the oral solution of pregabalin developed by Haibu Pharmaceutical was successfully selected!
01. Ruianxi® Pregabalin Oral Solution
The pregabalin oral solution has been approved for multiple indications worldwide, including postherpetic neuralgia, fibromyalgia, neuropathic pain due to spinal cord injury, diabetic peripheral neuropathy, and as an adjunctive therapy for partial seizures in patients aged one month and older. Both domestic and international guidelines consistently recommend pregabalin as the first-line treatment for postherpetic neuralgia (PHN) and fibromyalgia (FM).
Our product is equipped with a precise drug delivery device, making dose adjustments more convenient; at the same time, the oral solution form is easier to swallow than solid formulations, making it the first choice for elderly patients and those with swallowing difficulties due to epilepsy, stroke, or postherpetic neuralgia.
02. Strength Creates Quality - The Significance of Centralized Procurement is Major
Ruianxi® Pregabalin Oral Solution has successfully been selected in the tenth batch of national centralized procurement! This is not only a high recognition of Haibu Pharmaceutical's compliance qualifications and product quality but also a great blessing for many patients. With the implementation of the centralized procurement policy, Ruianxi® Pregabalin Oral Solution will be available at more favorable prices and broader coverage, benefiting more patients and effectively reducing their medication burden.
At the same time, Haibu Pharmaceutical will take this successful selection in the national centralized procurement as an opportunity to continuously improve product quality and technological innovation capabilities, launching more high-quality, efficient, and safe pharmaceutical products, allowing more patients to access affordable and high-quality medicines, bringing happiness and hope to the public!
Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as "Haibu Pharmaceutical") was established in 2005 and is a high-tech enterprise with "chemical drug research and development" as its core capability. It has a research and development center in Beijing, a pilot verification center for raw materials and formulations, and a GMP industrial production base, mainly engaged in the technical development and transfer of chemical drugs, MAH research and holding certificates, related applications for raw materials, and commercial supply of pharmaceutical intermediates. and the application for innovative and improved drug research and development, it has been awarded the title of "Top 20 Pharmaceutical R&D Companies in China" for several consecutive years and recognized as "Beijing Science and Technology Research and Development Institution," "National High-tech Enterprise," and "Beijing Yizhuang Enterprise Innovation Center."
Haibu Pharmaceutical has rich experience in the research and production transfer, registration, and application of various dosage forms such as chemical raw materials, oral solids, liquid preparations, sterile injections, and external preparations. The R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular, digestive system, and respiratory system.
Beijing Hope Pharmaceutical Co., Ltd.
